Nuvectis Pharma (NVCT) Share-based Compensation (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Share-based Compensation data on file, last reported at $8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 521.35% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $8.5 million (up 94.6% YoY), and the FY2025 full-year result was $6.0 million, up 24.17% from the prior year.
• Share-based Compensation improved to $8.5 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.5 million in Q1 2026 to a low of $156000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.1 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation tumbled 66.67% in 2022 and soared 798.72% in 2023, its largest moves.
• Tracing NVCT's Share-based Compensation over 5 years: stood at $482000.0 in 2022, then jumped by 153.11% to $1.2 million in 2023, then dropped by 6.48% to $1.1 million in 2024, then climbed by 29.36% to $1.5 million in 2025, then soared by 475.88% to $8.5 million in 2026.
• Business Quant data shows NVCT's Share-based Compensation at $8.5 million in Q1 2026, $1.5 million in Q4 2025, and $900000.0 in Q3 2025.